Another COVID-19 treatment, Xevudy (sotrovimab), has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease.

Developed by GSK and Vir Biotechnology, sotrovimab is a single monoclonal antibody. The drug works by binding to the spike protein on the outside of the COVID-19 virus. This in turn prevents the virus from attaching to and entering human cells, so that it cannot replicate in the body.

See: MHRA approves Xevudy (sotrovimab), a COVID-19 treatment found to cut hospitalisation and death by 79% – GOV.UK (www.gov.uk)